DRUG BRIGHT MINDS BIOSCIENCES INC

Bright Minds Biosciences to Participate at Three Healthcare Conferences in March

Bright Minds Biosciences to Participate at Three Healthcare Conferences in March

NEW YORK and VANCOUVER, British Columbia, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that Ian McDonald, Chief Executive Officer, and select members of senior management, will participate in three healthcare conferences, as follows:

TD Cowen 45th Annual Health Care Conference, Boston

Monday, March 3, 2025, at 1:10pm ET

Leerink Partners Global Healthcare Conference, Miami

Wednesday, March 12, 2025 (1x1 meetings)

BIO-Europe Spring, Milan

March 17-19, 2025

The live and archived webcasts will be accessible from the Company’s website at under Events and Presentation. The replay of the webcast will be accessible for 90 days.

About Bright Minds Biosciences

Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients’ lives.

Bright Minds Biosciences has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.

Contact Information

Alex Vasilkevich

Chief Operating Officer

Bright Minds Biosciences Inc.

T: 414-731-6422

E:

Website:

Investor Relations

Lisa M. Wilson

T: 212-452-2793

E:



EN
24/02/2025

Underlying

DRUGBRIGHT MINDS BIOSCIENCES INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BRIGHT MINDS BIOSCIENCES INC

 PRESS RELEASE
Free
DRUG BRIGHT MINDS BI...

Bright Minds Biosciences to Present at Upcoming Conferences

Bright Minds Biosciences to Present at Upcoming Conferences NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences: EVENT:TD Cowen 46th Annual Health Care ConferenceDATE:Wednesday, March 4, 2026TIME:9:10am ETWEBCAST: EVENT: Le...

February 25, 2026 1 EN
 PRESS RELEASE
Free
DRUG BRIGHT MINDS BI...

Bright Minds Biosciences Announces Closing of US$175 Million Public Of...

Bright Minds Biosciences Announces Closing of US$175 Million Public Offering NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) today closed its recently announced public offering of 1,945,000 common shares in the capital of the Company (the “Common Shares”) at a price of US$90.00 per Common Share for gross proceeds of US$175,050,000 (the “Offering”). In connection with the Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 291,750 Common Shares at the publi...

January 9, 2026 1 EN
 PRESS RELEASE
Free
DRUG BRIGHT MINDS BI...

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million P...

Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces the pricing of its previously announced public offering of 1,945,000 common shares in the capital of the Company (the “Common Shares”) at a price of $90.00 per Common Share for anticipated gross proceeds of $175,050,000 (the “Offering”). In connection with the Offering, the Company has granted the underwriters a 30-day option to purchase up to an...

January 8, 2026 1 EN
 PRESS RELEASE
Free
DRUG BRIGHT MINDS BI...

Bright Minds Biosciences Announces Launch of US$100 Million Public Off...

Bright Minds Biosciences Announces Launch of US$100 Million Public Offering NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces the launch of a public offering of common shares in the capital of the Company (the “Common Shares”) and, in lieu of Common Shares to investors that so choose, pre-funded warrants (the “Pre-Funded Warrants”) to purchase Common Shares, for aggregate gross proceeds of US$100 million (the “Offering”). In connection with the Offering, the Company intends to grant to the under...

January 6, 2026 1 EN
 PRESS RELEASE
Free
DRUG BRIGHT MINDS BI...

Bright Minds Biosciences Announces Positive Topline Results from Phase...

Bright Minds Biosciences Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE) BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% median reduction in the number of absence seizure ≥3s, p = 0.012DEE: 63.3% median reduction in major motor seizures REM sleep improvement in patients with Absence Seizures: mean 90% increase in REM sleep with no change in total sleep durationCompany has initiated preparations for gl...

January 6, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch